NAV 1800

Drug Profile

NAV 1800

Alternative Names: NAV-1800; RIGScan CR; RIGScan-CR49

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neoprobe
  • Developer Navidea Biopharmaceuticals
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Colorectal cancer

Most Recent Events

  • 03 Feb 2016 No recent reports on development identified - Phase-III for Colorectal cancer (Diagnosis, Metastatic disease) in USA (IV)
  • 26 Sep 2013 Phase-III clinical trials in Colorectal (diagnosis, metastatic disease) cancer in USA (IV)
  • 26 Sep 2013 Phase-III clinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top